Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer

$ 8.50

4.8
(90)
In stock
Description

Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.

Cancers, Free Full-Text

Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies - touchONCOLOGY

Overall survival of patients stratified by estrogen receptor (ER)

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles - Modern Pathology

Simplified ER and HER2 signalings' cross-talk. Estrogens (E) act via a

An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Schematic diagram of estrogen receptor signaling in breast cancer.

Clinical classi fi cation of invasive breast cancer based on expression

Estrogen/Progesterone Receptors (ER/PR Receptors)

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer Prognosis

Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor